Dsm Firmenich Ag (DSMFF) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for joining today's call. I'm sitting here with Rolf Smets, our CFO. This morning, we published our first quarter 2025 trading update, together with a presentation to investors, which you can find on our website. Here you can also find our disclaimers about forward-looking statements. Following Rolf's opening comments, we will open the line for questions. Importantly, and as a reminder, sell-side analysts who want to ask questions will need to register via the questioner's link, which they can find on our website in the financial calendar. If you have not done so yet, you can still switch now. And with that, Rolf, please go ahead. Well, thanks, Dave, and good morning. Good morning from sunny Maastricht. So at least sun is shining and happy that it's coupled with today. We'll take you through our quarter one results and a few of the strategic updates along the way as well. And we'll zoom in into the business units as usual. But let me start with the overall picture and framing of our performance to date. We started the year in a good way. Overall, you see already a couple of numbers on this slide. Overall, 8% organic growth. Very encouraging start of the year. And obviously, that translated into a very nice step up in profitability. We've seen a 40% step up in EBITDA and a margin of 20%. And we'll come back with some more detail, both for the group and the BUs in a little while. So bear with me on that. But very pleased with that start of the year. On the strategic side, we also made good progress at the full year results. We already talked about the sale to Novo Nises of the feed enzymes business. We're well on the way in completing that. We're waiting on the final go of two smaller jurisdictions. So Confident that that will close into the...